Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

NCT00037583

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-59 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All adult patients with relapsed or refractory AML, as well as younger de novo AML patients are eligible for the study

- Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study

- Phase II will only allow enrollment of younger de novo AML

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- AML following an antecedent hematologic disorder (myelodysplasia or
myeloproliferation) of greater than 2 months duration


- De novo patients with M3 AML


- AML secondary to exposure to chemotherapy or radiation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ACUTE MYELOID LEUKEMIAGLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
NCT04051996
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
NCT00037583
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
NCT00037596
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
NCT00161668
  1. Tucson, Arizona
  2. Berkely, California
  3. Burbank, California
  4. Concord, California
  5. Loma Linda, California
  6. Los Angeles, California
  7. San Francisco, California
  8. Sylmar, California
  9. Denver, Colorado
  10. Boynton Beach, Florida
  11. Plantation, Florida
  12. Stuart, Florida
  13. Tamarac, Florida
  14. Chicago, Illinois
  15. Chicago, Illinois
  16. Chicago, Illinois
  17. Chicago, Illinois
  18. Indianapolis, Indiana
  19. Iowa City, Iowa
  20. Lexington, Kentucky
  21. Louisville, Kentucky
  22. Shrevport, Louisiana
  23. Ann Arbor, Michigan
  24. Grand Rapids, Michigan
  25. Kalamazoo, Michigan
  26. Kalamazoo, Michigan
  27. Columbia, Missouri
  28. St. Louis, Missouri
  29. Neptune, New Jersey
  30. Albuquerque, New Mexico
  31. Bronx, New York
  32. Buffalo, New York
  33. New Hyde Park, New York
  34. New York, New York
  35. New York, New York
  36. Valhalla, New York
  37. Durham, North Carolina
  38. Winston-Salem, North Carolina
  39. Bismarck, North Dakota
  40. Akron, Ohio
  41. Canton, Ohio
  42. Cincinnati, Ohio
  43. Cleveland, Ohio
  44. Oklahoma City, Oklahoma
  45. Portland, Oregon
  46. Hershey, Pennsylvania
  47. Philadelphia, Pennsylvania
  48. Philadelphia, Pennsylvania
  49. Pittsburgh, Pennsylvania
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Nashville, Tennessee
  53. Houston, Texas
  54. Temple, Texas
  55. Arlington, Virginia
  56. Richmond, Virginia
  57. Charleston, West Virginia
  58. Morgantown, West Virginia
  59. Appleton, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Official Title  ICMJE A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML)
Brief Summary The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE Acute Myeloid Leukemia
Intervention  ICMJE Drug: Gemtuzumab Ozogamicin
Study Arms  ICMJE Not Provided
Publications * Hibma J, Knight B. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia. Clin Pharmacokinet. 2019 Mar;58(3):335-347. doi: 10.1007/s40262-018-0699-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 20, 2009)
69
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE September 2003
Actual Primary Completion Date September 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • All adult patients with relapsed or refractory AML, as well as younger de novo AML patients are eligible for the study
  • Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study
  • Phase II will only allow enrollment of younger de novo AML

Exclusion Criteria:

  • AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of greater than 2 months duration
  • De novo patients with M3 AML
  • AML secondary to exposure to chemotherapy or radiation
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 59 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00037583
Other Study ID Numbers  ICMJE 0903B1-206
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP